Compact Bone-Derived Multipotent Mesenchymal Stromal Cells (MSCs) for the Treatment of Sjogren's-like Disease in NOD Mice

Methods Mol Biol. 2017:1553:25-39. doi: 10.1007/978-1-4939-6756-8_3.

Abstract

Compact bone (cortical or dense bone) is among the organs that contain multipotent mesenchymal stromal cells (MSCs). Unlike bone marrow plugs where MSCs were initially isolated, compact bone has minimal (amount of) hematopoietic cells and thus facilitates the MSCs isolation process. In vitro, MSCs from compact bone show multipotency and differentiation into mesenchymal tissues such as bone, adipose, and cartilage, under certain conditions. MSCs therapy has been promising in preclinical and clinical studies against autoimmune diseases. Not only can MSCs replace the lost tissue through their regenerative properties, but they can also control the autoimmune attacks by immunoregulatory cytokines. This protocol describes the use of compact bone-derived MSCs to preserve salivary function (saliva flow/output) in the NOD (nonobese diabetic) mouse model affected with Sjogren's-like disease.

Keywords: Autoimmune diseases; Compact bone; Hyposalivation; MSCs; Mesenchymal stromal cells; Nonobese Diabetic (NOD) mouse; Saliva; Sjogren’s syndrome; Sjogren’s-like disease; Xerostomia.

MeSH terms

  • Adipogenesis
  • Animals
  • Biomarkers
  • Cell Culture Techniques
  • Cell Differentiation
  • Cell Separation / methods
  • Chondrogenesis
  • Colony-Forming Units Assay
  • Cortical Bone / cytology*
  • Disease Models, Animal
  • Immunophenotyping
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology*
  • Mesenchymal Stem Cells / metabolism
  • Mice
  • Mice, Inbred NOD
  • Mice, Transgenic
  • Osteogenesis
  • Sjogren's Syndrome / etiology
  • Sjogren's Syndrome / therapy*

Substances

  • Biomarkers

Grants and funding